Applications of artificial intelligence and machine learning to health care and research have been exploding over the last year—and sometimes backfiring, as researchers negotiate the learning curve. There is great hope, however, that these technologies will reduce drug discovery times and ultimately enable precision medicine. Is a computational approach the awaited disruption that will speed time and lower costs of research and development? Or will human biology outsmart our best efforts to decode it algorithmically?

Moderator
Rick Berke Executive Editor, STAT

Speakers
Rowan Chapman Head, Johnson and Johnson Innovation California

Iya Khalil
Co-Founder, Chief Commercial Officer and Executive Vice President, GNS Healthcare

Lloyd Minor
Dean, Stanford Medicine

George Yancopoulos
Chief Scientific Officer, Regeneron

Megan Zweig
Director of Research, Rock Health